Supplementary Figures S1-S12 and Supplementary Tables S1-S3 from Novel Glycosylated VEGF Decoy Receptor Fusion Protein, VEGF-Grab, Efficiently Suppresses Tumor Angiogenesis and Progression

Supplementary Figure S1. Sequence Alignment of VEGF-Grab1, VEGF-Grab3, and VEGF-Trap; Supplementary Figure S2. Analysis of N-linked Glycosylation for VEGF-Grabs and VEGF-Trap; Supplementary Figure S3. Analysis of O-linked Glycosylation in VEGF-Grab1; Supplementary Figure S4. VEGF-Grab3 displays low binding to tumor ECM; Supplementary Figure S5. Pharmacokinetic profile of VEGF-Grab1 and VEGF-Grab3; Supplementary Figure S6. Tissue accumulation of VEGF-Trap and VEGF-Grab3; Supplementary Figure S7. VEGF-Grabs or VEGF-Trap have no effects on VEGFR2 signalling, EC survival, migration, and tube formation in the absence of VEGFA; Supplementary Figure S8. Dose-dependent Inhibition of VEGFR2 Signalling with Anti-VEGF Therapy; Supplementary Figure S9. Histologic Analyses of Vital Organs after Anti-VEGF Therapy; Supplementary Figure S10. VEGF-Grab effectively suppresses the growth of established bulky macroscopic tumors; Supplementary Figure S11. Histological analyses of the kidney and liver after dose dependent anti-VEGF therapy; Supplementary Figure S12. Combination Therapy of VEGF-Grab3 and Cisplatin Enhances Intratumoral Apoptosis; Supplementary Table S1. Primer sequences for site-directed mutagenesis; Supplementary Table S2. Primer sequences for Quantitative Real Time PCR; Supplementary Table S3. Antibodies.